Bussiness Overview

Pipelines

NanoCarrier's business consists of four main pipelines, which are now in clinical and preclinical study, and four newly developed pipelines. Main four products are micellar nanoparticles encapsulating existing potent anticancer agents or their analogues. Therefore, the risk of development is relatively lower than that of new chemical compounds. NanoCarrier aims to expand our business of globally.

Products under development
Main Pipelines
Product Indication Region for
clinical studies		 Development phase
Stage Status
Paclitaxel Micelle
(NK105)(Note 1)		 Gastric cancer Japan Phase II
clinical study
completed
  • Licensed to Nippon Kayaku Co. Ltd. exclusively for Japan and Asia.
  • Phase I Clinical study could be conducted without prophylactic medication for adverse reactions.
  • Phase II clinical study started on November 2007 has been completed, and Phase III clinical study is now in preparation
  • Phase I clinical study with Breast cancer started on August 2010.
Breast cancer Japan Phase I
clinical study
Nanoplatin®
(NC-6004)		 Pancreatic cancer Taiwan
Singapore		 Phase II clinical study
  • Phase I study in the United Kingdom was terminated at March 2008 by NanoCarrier.
  • NanoCarrier granted to OEP an exclusive license for commercialization in the territory of East Asia (excluding Japan and Main China), South-East Asia and Oceania to start the next step of clinical study.
  • IND was approved in December 2008.(Taiwan)
  • Nanocarrier and OEP are conducting the Phase II clinical study in Asia for pancreatic cancer since July 2011.
DACH-Platin Micelle
(NC-4016)		 Cancer
(Note 2)		 Europe Phase I clinical study
  • Debiopharm operated the study in UK and France until March,2011.
Epirubicin Micelle
(NC-6300)		 Cancer
(Note 2)		 JapanPreclinical
study
  • Licensed and co-development to KOWA company Ltd.

New pipelines
Product Indication Region for clinical studies Development phase
Stage
Protein Micelle Hemophilia - Research Collaboration Agreement with
LFB Biotechnologies(negotiation)
Not decided
(Note 3)		 - Feasibility Study
siRNA Micelle Not decided
(Note 3)		 - Feasibility Study
Sensor Linked Micelle Cancer
(Note 2)		 - Feasibility Study
Docetaxel Micelle Cancer
(Note 2)		 - Feasibility Study completed.
(Note 1) NK105 is the product development code used for this product at Nippon Kayaku Co., Ltd.
(Note 2) DACH-Platin Micelle (NC-4016), Sensor Linked Micelle, Epirubicin Micelle, and Docetaxel Micelle are indicated for cancer, but the type(s) of cancer is currently not specified. Specific indications are expected to be determined following future progress in research and development, before the start of phase II clinical studies.
(Note 3) Protein Micelle and siRNA Micelle are currently not indicated for specific diseases because indications will differ depending on the type of product encapsulated in micellar nanoparticles.
Pagetop